S21 Stock Chart & Stats
€0.01
<€0.01(36.36%)
At close: 4:00 PM EDT
€0.01
<€0.01(36.36%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
€898.96K
Enterprise Value€4.15
Total Cash (Recent Filing)€564.00K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta13.63
Next Earnings
Nov 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,797,314,100
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.93
Price to Sales (P/S)0.64
P/FCF Ratio-6.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€5.44M
Bulls Say, Bears Say
Bulls Say
Long-term Revenue GrowthThe substantial multi-year revenue increase indicates that S2Medical has expanded its commercial base and product adoption. Although recent growth has weakened, the larger revenue platform provides a foundation for recovery if execution and demand stabilize.
Low Financial LeverageAn essentially debt-free balance sheet limits interest and refinancing risk while preserving financial flexibility. This gives S2Medical more capacity to manage operating volatility, invest in its business, or pursue funding options without substantial leverage constraints.
Demonstrated Cash GenerationThe strong cash generation achieved in 2024 shows that the business can fund itself when profitability is healthy. This provides evidence of potential operating leverage and a path toward self-funding if margins and execution return to stronger levels.
Bears Say
Volatile Revenue TrajectoryThe reversal from strong growth to declines reduces confidence in demand durability and forecasting reliability. Continued volatility could weaken operating leverage, make resource planning harder, and delay the ability to convert the expanded revenue base into consistent returns.
Unstable ProfitabilityLarge renewed losses after a profitable 2024 indicate that earnings quality and margin sustainability remain unproven. Persistent weak profitability can erode equity value, constrain reinvestment, and increase dependence on future operational improvements or external financing.
Renewed Cash BurnNegative operating and free cash flow show that current operations are not funding the business despite the low-debt balance sheet. If losses persist, ongoing cash burn could create future funding needs and limit investment in products, sales, and growth initiatives.
S21 FAQ
What was S2Medical AB Class B’s price range in the past 12 months?
Currently, no data Available
What is S2Medical AB Class B’s market cap?
S2Medical AB Class B’s market cap is €898.96K.
When is S2Medical AB Class B’s upcoming earnings report date?
S2Medical AB Class B’s upcoming earnings report date is Nov 30, 2026 which is in 59 days.
How were S2Medical AB Class B’s earnings last quarter?
S2Medical AB Class B released its earnings results on Aug 21, 2026. The company reported €0 earnings per share for the quarter.
Is S2Medical AB Class B overvalued?
According to Wall Street analysts S2Medical AB Class B’s price is currently Overvalued.
Does S2Medical AB Class B pay dividends?
S2Medical AB Class B does not currently pay dividends.
What is S2Medical AB Class B’s EPS estimate?
S2Medical AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does S2Medical AB Class B have?
S2Medical AB Class B has 1,797,314,100 shares outstanding.
What happened to S2Medical AB Class B’s price movement after its last earnings report?
S2Medical AB Class B reported an EPS of €0 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of S2Medical AB Class B?
Currently, no hedge funds are holding shares in DE:S21
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
S2Medical AB Class B
S2Medical AB (publ) focuses on the development, production, and commercialization of advanced wound care solutions, specifically targeting burns and chronic wounds. Their product range features INSTAQRETT, a sterile, disposable tool for mechanical debridement; EPIPROTECT SafeStop, designed to control bleeding; and Instagraft, a single-use medical device for treating complex and prolonged wounds. The company also supplies EPIPROTECT tissue replacement products and INSTABIND-branded bandages, which are known for being washable, waterproof, and self-adhesive. Furthermore, S2Medical distributes Silverlon dressings, which facilitate the delivery of silver ions to the wound. In addition to its product offerings, the company operates specialized wound healing centers known as S2Clinic. Founded in 2013, S2Medical is headquartered in Linköping, Sweden.